¡¾µ÷¼Á¡¿±±¾©Ê¯ÓÍ»¯¹¤Ñ§Ôº2024Äê16¸öרҵ½ÓÊܵ÷¼Á
²é¿´: 2486  |  »Ø¸´: 17
±¾Ìû²úÉú 1 ¸ö DRDEPI £¬µã»÷ÕâÀï½øÐв鿴

ronalbeck

Òø³æ (ÕýʽдÊÖ)


[½»Á÷] ÏÈÉùÒ©ÒµÒ»ÀàÐÂÒ©°¬À­ÄªµÂ»ñÅúÒÑÓÐ15È˲ÎÓë

ÏÈÉùÒ©ÒµÒ»ÀàÐÂÒ©°¬À­ÄªµÂ»ñÅú  
2011-09-01  À´Ô´£ºÃ×ÄÚÍø   


      ºËÐÄÌáʾ£ºÏÈÉùÒ©Òµ¹«²¼Æä×ÔÖ÷Ñз¢µÄÖÎÁÆÀà·çʪÐԹؽÚÑ×ÐÂÒ©°¬À­ÄªµÂƬ (ÉÌÆ·Ãû£º°¬µÃÐÁ)Õýʽ»ñµÃ¹ú¼ÒʳƷҩƷ¼à¶½¹ÜÀí¾Ö£¨SFDA£©¹ú¼ÒÒ»ÀàÐÂÒ©Ö¤Êé¼°Ò©Æ·×¢²áÅúÎÄ¡£°¬µÃÐÁÊÇÈ«ÇòµÚÒ»¸öÉÏÊеݬÀ­ÄªµÂÖƼÁ¡£  

Ã×ÄÚÍøר¸å(Ñо¿Ô± Îâ¿¡½Ü)8ÔÂ24ÈÕ,ÏÈÉùÒ©ÒµÔÚÆä¹ÙÍø¹«²¼,Æä×ÔÖ÷Ñз¢µÄÐÂÒ©°¬À­ÄªµÂƬ (ÉÌÆ·Ãû:°¬µÃÐÁ)Õýʽ»ñµÃ¹ú¼ÒʳƷҩƷ¼à¶½¹ÜÀí¾Ö(SFDA)¹ú¼ÒÒ»ÀàÐÂÒ©Ö¤Êé¼°Ò©Æ·×¢²áÅúÎÄ¡£Åú×¼ÎĺÅΪ¹úÒ©×¼×ÖH20110084,¼ÁÐÍΪƬ¼Á,¹æ¸ñ25mg,ÏÈÉùҩҵͬʱ»ñµÃ°¬À­ÄªµÂµÄÔ­ÁÏÒ©ÅúÎÄ¡£

¾Ý½éÉÜ,°¬µÃÐÁÊÇÈ«ÇòµÚÒ»¸öÉÏÊеݬÀ­ÄªµÂÖƼÁ,Ò²ÊÇÒ»¸öȫнṹÀàÐ͵ÄDMARDS(Disease Modifying Anti-rheumatic Drugs,¼²²¡ÐÞÊο¹·çʪҩ)Ò©Îï,ÆäÖ÷ÒªÊÊӦ֢Ϊ»î¶¯ÐÔÀà·çʪÐԹؽÚÑ×,¿ÉÏÔÖø¸ÄÉÆÀà·çʪÐԹؽÚÑ×»¼Õߵļ²²¡Ö¢×´ºÍÑ×Ö¢Ö¸±ê,¼õÇỼÕßµÄÍ´¿à¡£

´ÓÃ×ÄÚÍø-»¯Ñ§Ò©ÁÙ´²ÓÃÒ©¾ºÕù¸ñ¾ÖÁ˽⵽,ÎÒ¹úÖÎÁÆÀà·çʪÐԹؽÚÑ×Ò©ÎïÖ÷ÒªÓа±»ùÆÏÌÑÌÇ¡¢Â¹¹Ï¶àëÄ¡¢·ú±ÈÂå·Ò¡¢ÈûÀ´Îô²¼µÈ,Êг¡¸ñ¾ÖÈçÏÂͼ¡£




½ñÄêÒÔÀ´,Óжà¸öÒ»ÀàÐÂÒ©»ñÅú,Ïà¹ØÇé¿öÈçϱí:

Ò©Ãû
¹«Ë¾
ÏêÇé

ÑÎËá°£¿ËÌæÄáƬ
±´´ïÒ©Òµ
Ò»ÀàÐÂÒ©ÑÎËá°£¿ËÌæÄáÉÏÊÐ

°¬ÈðÎô²¼Æ¬
ºãÈðÒ½Ò©
Ò»ÀàÐÂÒ©°¬ÈðÎô²¼»ñÅú

×¢ÉäÓÃÖØ×éÈËÄò¼¤Ã¸Ô­
ÉϺ£ÌìÊ¿Á¦Ò©Òµ
¶þ¼¾¶È¶à¸öÒ»ÀàÐÂÒ©»ñÉú²úÅúÎÄ

×¢ÉäÓÃÍ·æßÇúËÉÄÆÊæ°Í̹ÄÆ
Ïæ±±Íþ¶ûÂü
  

°¬À­ÄªµÂƬ
ÏÈÉùÒ©Òµ
»Ø¸´´ËÂ¥
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
2Â¥2011-09-01 14:22:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

hardee

Ìú¸Ëľ³æ (ÖªÃû×÷¼Ò)

´Ë²ÝÓÐÖ÷~

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
zhychen2008(½ð±Ò+1, DRDEPI+1): ¶àлÌṩÐÅÏ¢ 2011-09-03 16:03:22


Meantime, Eisai and Toyama Chemical Co have submitted a marketing authorisation application  for T-614 (iguratimod), an anti-rheumatic agent being jointly developed in Japan by the two companies.

T-614 is a novel disease modifying anti-rheumatic drug originally discovered by Toyama and an MAA was previously submitted in 2003. However, the application was temporarily withdrawn in 2009 in order to conduct an additional clinical study which subsequently confirmed with statistical significance the efficacy of the agent as an add-on therapy for use with the standard of care, methotrexate.

http://www.pharmatimes.com/Artic ... epsy_portfolio.aspx

Ö»ÄÜ˵ÊÇÏÈÉùµÄÔËÆøºÃÁË¡£¡£¡£

[ Last edited by hardee on 2011-9-1 at 15:17 ]
°²µÃ´ÙÏ¥£¬¿É¹²Æ½Éú¡£
3Â¥2011-09-01 14:58:07
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

zhenyu19

ľ³æ (СÓÐÃûÆø)

à½à½

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
¹úÍâûÅú£¬¹úÄÚÏÈÅúÁË£¿Õâ¾ÍÊÇ´«ËµÖеÄ1Àà°¡¡£
4Â¥2011-09-01 16:16:21
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

Ò©µÀÈË

ÈÙÓþ°æÖ÷ (ÎÄ̳¾«Ó¢)

¾»ÓÉ»àÉú£¬Ã÷´Ó霳ö

ÓÅÐã°æÖ÷ÓÅÐã°æÖ÷

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
zhychen2008(½ð±Ò+1): ¶àл²ÎÓë 2011-09-03 16:03:38
DMARDSÔçÒÑÊôÓÚ¶þÏßÓÃÒ©,ÓкÎÒâÒå
À´Ê±ºúͿȥʱÃÔ£¬¿ÕÔÚÈ˼ä×ßÕâ»Ø¡£Î´ÔøÉúÎÒË­ÊÇÎÒ£¬ÉúÎÒÖ®ºóÎÒÊÇË­£¿³¤´ó³ÉÈË·½ÖªÎÒ£¬ºÏÑÛëüëÊÓÖÊÇË­£¿²»Èç²»À´Ò²²»È¥£¬ÒàÎÞ·³ÄÕÒàÎÞ±¯¡£
5Â¥2011-09-02 09:48:17
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

dudu235

ľ³æ (ÖøÃûдÊÖ)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
ÏÈÉùºãÈð±´´ïÐÂÒ©Ñз¢ÒѾ­ÁìÏÈÁË Á˲»Æð Íþ¶ûÂüÔõôû̫Ìý˵¹ý£¿
ʱ¼äºã¾ÃÔ¶ËêÔ²»ÈÄÈË
6Â¥2011-09-02 10:28:20
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

lpw106

Òø³æ (СÓÐÃûÆø)

»¹¿ÉÒÔ
7Â¥2011-09-02 11:03:19
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ö§³Ö°É£¡
8Â¥2011-09-02 11:04:45
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

1994yw

ľ³æ (ÕýʽдÊÖ)

¡ï ¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
zhychen2008(½ð±Ò+1): ¸Ðл»ØÌû½»Á÷ 2011-09-03 16:04:12
¶ÔÓÚ°¬À­ÄªµÂÕâ¸öËùνµÄÒ»ÀàÐÂÒ©£¬Ô¤¼ÆδÀ´»¹ÓÐÁ½¸öÅúÎÄÏÂÀ´£¬¾Í¸ú¶÷Ì濨ΤһÑù£¬12¸öÔÂÄÚÁ¬ÐøÅú³öÀ´Èý¸öÒ»ÀàÐÂÒ©¡£
ÕæÓÐÒâ˼£¡
9Â¥2011-09-02 11:06:51
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû

iijs

½ð³æ (ÕýʽдÊÖ)

¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû
»áÅúµØ£¬ÖØ´óרÏî´ÕÊýÒ²ÒªÅú¡£
10Â¥2011-09-02 11:50:16
ÒÑÔÄ   »Ø¸´´ËÂ¥   ¹Ø×¢TA ¸øTA·¢ÏûÏ¢ ËÍTAºì»¨ TAµÄ»ØÌû
Ïà¹Ø°æ¿éÌøת ÎÒÒª¶©ÔÄÂ¥Ö÷ ronalbeck µÄÖ÷Ìâ¸üÐÂ
×î¾ßÈËÆøÈÈÌûÍƼö [²é¿´È«²¿] ×÷Õß »Ø/¿´ ×îºó·¢±í
[½Ìʦ֮¼Ò] ¸Õ²©Ê¿±ÏÒµ£¬ÈëÖ°ÆÕͨһ±¾¸ßУ +4 ±£³Ö¼¡·ô 2024-04-20 4/200 2024-04-20 10:39 by äÆÃðµú
[ÕÒ¹¤×÷] ¼ÒÏç¶þ±¾¸ßУ/Ñغ£´«Í³Ë½Æó£¬ÈçºÎ¾ñÔñ£¿ 10+7 »¯Ñ§Ïï 2024-04-15 16/800 2024-04-20 10:28 by Ïà·ê
[¿¼²©] ɽ¶«´óѧ»¯Ñ§Ó뻯¹¤Ñ§ÔºÁõÀÚ¿ÎÌâ×鲩ʿÑо¿ÉúÕÐÉúÆôÊ +3 sdorganic 2024-04-17 5/250 2024-04-19 17:04 by 368ghnf
[ÂÛÎÄͶ¸å] ¹ú¼ÒÖصãÑз¢¼Æ»®ÂÛÎÄ¿ÉÒÔ·¢MDPIÀïµÄÆÚ¿¯Âð +4 lin_2018 2024-04-17 4/200 2024-04-19 08:46 by TsolmonZ
[»ù½ðÉêÇë] ¹ú×ÔÈ»ÇàÄê»ù½ðÖ»ÓÐһƪÄܵÚÒ»±ê×¢£¬ÆäËû¶¼Êǵڶþ±ê×¢ÄܽáÌâÂ𣿠10+4 lice_1987 2024-04-18 6/300 2024-04-19 08:29 by kudofaye
[¿¼ÑÐ] 267Çóµ÷¼Á +3 ¹¤¿Æ²ÄÁÏ267 2024-04-15 3/150 2024-04-18 19:45 by lature00
[¿¼ÑÐ] ¹¤Ñ§322£¬Ó¢ÓïÁù¼¶Çóµ÷¼Á +3 domax 2024-04-17 10/500 2024-04-17 21:25 by ¶«·½»¨Ô°Ð¡Íò
[¿¼ÑÐ] ÍÁľ¹¤³Ì281Çóµ÷¼Á +4 ÇÇÙâľ 2024-04-13 4/200 2024-04-16 21:40 by zjl½¥Ðн¥Ô¶
[»ù½ðÉêÇë] ³Ù¹ú̩ͨ¹ýÏòѧÉú·¢·ÅÀÍÎñ·ÑÔÙ»ØÊյķ½Ê½Ì×È¡¿Æѧ»ù½ðÖصãÏîÄ¿ +6 babu2015 2024-04-13 7/350 2024-04-16 20:32 by sundiv
[¿¼ÑÐ] 347Çóµ÷¼Á +3 º®³½ovo 2024-04-15 7/350 2024-04-16 19:05 by º®³½ovo
[¿¼ÑÐ] 296Çóµ÷¼Á +3 Cclocomotive 2024-04-16 4/200 2024-04-16 10:04 by 19862091
[¿¼ÑÐ] 329Çóµ÷¼Á +18 ÍõÓô½à¹þ¹þ¹þ 2024-04-14 26/1300 2024-04-15 19:10 by mumin1990
[ÂÛÎÄͶ¸å] with efitor Ô½¾ÃÊDz»ÊÇÔ½ÈÝÒ׾ܸ塣ÎÒµÄÒѾ­Ò»¸ö¶àÔÂÁË +5 lizhengke06 2024-04-14 5/250 2024-04-15 18:33 by jonewore
[¿¼ÑÐ] 328Çóµ÷¼Á +3 send rgsc 2024-04-14 7/350 2024-04-15 18:17 by zw_muchong
[Óлú½»Á÷] ÇóÒÒ¶þ´¼¼ì²â·½·¨ 13+3 YaShang 2024-04-14 4/200 2024-04-15 15:16 by Byltest
[¿¼ÑÐ] 273Çóµ÷¼Á +5 LateÍñ°² 2024-04-15 7/350 2024-04-15 13:01 by LateÍñ°²
[¿¼ÑÐ] »¯Ñ§¡¢²ÄÁÏÀà×îºóµ÷¼Á»ú»á£¡£¡£¡ +3 ¼ÓÓÍŬÁ¦¾ÍºÃ 2024-04-14 10/500 2024-04-15 09:05 by ÈÎpen
[¿¼ÑÐ] 274Çóµ÷¼Á +5 Ëĸö´ó×Ö£¬ÄãµÎº 2024-04-13 6/300 2024-04-15 00:01 by Ëĸö´ó×Ö£¬ÄãµÎº
[¿¼ÑÐ] 290Çóµ÷¼Á +3 Ñîyhr 2024-04-14 5/250 2024-04-14 21:50 by coco1981
[¿¼ÑÐ] 338Çóµ÷¼Á +3 18280338551 2024-04-14 5/250 2024-04-14 10:03 by tcni
ÐÅÏ¢Ìáʾ
ÇëÌî´¦ÀíÒâ¼û